[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Beone Medicines Ltd (ONC)

Beone Medicines Ltd (ONC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 34,245,804
  • Shares Outstanding, K 109,720
  • Annual Sales, $ 5,343 M
  • Annual Income, $ 286,930 K
  • EBIT $ 447 M
  • EBITDA $ 589 M
  • 60-Month Beta 0.50
  • Price/Sales 6.51
  • Price/Cash Flow 81.11
  • Price/Book 7.31

Options Overview Details

View History
  • Implied Volatility 45.64% (+1.39%)
  • Historical Volatility 32.78%
  • IV Percentile 52%
  • IV Rank 40.99%
  • IV High 56.45% on 11/05/25
  • IV Low 38.14% on 01/16/26
  • Expected Move (DTE 4) 12.24 (3.94%)
  • Put/Call Vol Ratio 0.05
  • Today's Volume 20
  • Volume Avg (30-Day) 65
  • Put/Call OI Ratio 1.18
  • Today's Open Interest 2,866
  • Open Int (30-Day) 3,210
  • Expected Range 298.51 to 322.99

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 19 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $0.99
  • Number of Estimates 2
  • High Estimate $1.08
  • Low Estimate $0.90
  • Prior Year $0.84
  • Growth Rate Est. (year over year) +17.86%

Price Performance

See More
Period Period Low Period High Performance
1-Month
289.54 +7.33%
on 04/29/26
328.39 -5.37%
on 04/17/26
+1.09 (+0.35%)
since 04/10/26
3-Month
271.47 +14.47%
on 03/24/26
372.73 -16.63%
on 02/24/26
-40.52 (-11.54%)
since 02/11/26
52-Week
218.31 +42.34%
on 05/14/25
385.22 -19.33%
on 11/17/25
+78.76 (+33.95%)
since 05/09/25

Most Recent Stories

More News
BeOne Medicines Announces First Quarter 2026 Financial Results and Business Updates

Total global revenues of $1.5 billion for the first quarter, an increase of 35% from the prior year ...

ONC : 310.75 (-0.44%)
BeOne Medicines Delivers Quarterly Profit but Revenue Guidance Tests Investor Conviction

Barchart Research What to Expect from ONC Earnings ONC Generated May 5, 2026 Current Price $297.49 EPS Estimate $$0.73 Consensus Rating Strong Buy Average Move 4.66% BeOne Medicines Delivers Quarterly...

ONC : 310.75 (-0.44%)
U.S. FDA Grants Priority Review to BeOne Medicines’ TEVIMBRA in First-Line HER2+ GEA

TEVIMBRA plus ZIIHERA and chemotherapy regimen delivered statistically significant median OS of 26.4 months, an unprecedented result in this challenging disease Results...

ONC : 310.75 (-0.44%)
BeOne Medicines to Announce First Quarter 2026 Financial Results on May 6

BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, will report its first quarter 2026 financial results on Wednesday, May 6, 2026 before the financial markets open....

ONC : 310.75 (-0.44%)
BeOne Medicines Announces Fourth Quarter and Full Year 2025 Financial Results, Highlighting Global Success of BRUKINSA and Foundational Oncology Leadership

Total global revenues of $1.5 billion and $5.3 billion for the fourth quarter and full year, increases of 33% and 40% from the prior-year periods Global...

ONC : 310.75 (-0.44%)
BeOne Medicines to Present at Upcoming Investor Conferences

BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the Company will participate in fireside chats at four upcoming investor conferences: ...

ONC : 310.75 (-0.44%)
BeOne Medicines to Announce Fourth Quarter and Full Year 2025 Financial Results on February 26

BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, will report its fourth quarter and full year 2025 financial results on Thursday, February 26, 2026 before the financial...

ONC : 310.75 (-0.44%)
BeOne Medicines Highlights Global Oncology Leadership at 44th Annual J.P. Morgan Healthcare Conference

Company outlines foundational hematology leadership, multiple 2026 data catalysts, a unique global clinical development superhighway, and continued financial excellence

ONC : 310.75 (-0.44%)
ZIIHERA Plus TEVIMBRA and Chemotherapy: A Potential New Standard for First-Line HER2+ Advanced GEA

Combination therapy showed compelling survival and disease control compared to current standard, regardless of PD-L1 status High GEA burden in Asia, where BeOne holds...

ONC : 310.75 (-0.44%)
BeOne Medicines to Present at the 44th Annual J.P. Morgan Healthcare Conference

BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will participate in the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13,...

ONC : 310.75 (-0.44%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

BeOne Medicines is an oncology company which involved in discovering and developing treatments to cancer patients. BeOne Medicines, formerly known as BeiGene Ltd., is based in SAN CARLOS, Calif.

See More

Key Turning Points

3rd Resistance Point 324.96
2nd Resistance Point 321.48
1st Resistance Point 316.12
Last Price 310.75
1st Support Level 307.27
2nd Support Level 303.78
3rd Support Level 298.42

See More

52-Week High 385.22
Fibonacci 61.8% 321.46
Last Price 310.75
Fibonacci 50% 301.77
Fibonacci 38.2% 282.07
52-Week Low 218.31

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.